Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Dean Petkanas
AddedMar 31, 2024
UpdatedMay 31, 2026
Dean Petkanas

Dean Petkanas

Co-Founder, Kannalife Sciences

CrunchbaseLinkedIn

Dean Petkanas's Career

Kannalife Sciences
Kannalife Sciences

Doylestown, PA, US

Co-Founder
Neuropathix
Neuropathix

Doylestown, PA, US

CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Dean Petkanas's Career

Kannalife Sciences
Kannalife Sciences
Seed$4.5M52010Doylestown, PA, US
Co-Founder

Leadership at Kannalife Sciences

Timothy ScottTimothy ScottBoard Member
Robert MalasekRobert MalasekBoard Member

Similar to Kannalife Sciences

NeuropathixNeuropathixDoylestown, PA, USTherapeuticsest. 2010NeuropathixDoylestown, PA, US · est. 2010

Neuropathix: An American biopharmaceutical firm specializing in R&D of pain management therapies.

Public3
Panacea Life Sciences HoldingsPanacea Life Sciences HoldingsGolden, CO, USCannabinoids, Nutraceuticalsest. 2016Panacea Life Sciences HoldingsGolden, CO, US · est. 2016

Panacea Life Sciences: Cultivating wellness with nature, nurture, and science.

Public · $7M19
Pono Life SciencesPono Life SciencesHonolulu, HI, USMedical Cannabisest. 2015Pono Life SciencesHonolulu, HI, US · est. 2015

Pono Life Sciences: A Honolulu-based medical organization providing cannabis healthcare.

Series A · $5.3M6
WellcanaWellcanaLittle Rock, AR, USCBD Products, Pharmaceuticalsest. 2019WellcanaLittle Rock, AR, US · est. 2019

Wellcana: A biopharmaceutical firm specializing in standardized cannabinoid therapies and CBD product development.

Seed · $18.9M30
Neuropathix
Neuropathix
Public32010Doylestown, PA, US
CEO· C-Suite · Management

Leadership at Neuropathix

Dean PetkanasDean PetkanasBoard Member
Tage HonoréTage HonoréBoard Member
Thoma KikisThoma KikisBoard Member

Similar to Neuropathix

NeuroTherapeutics PharmaNeuroTherapeutics PharmaChicago, IL, USPharmaceuticals, Therapeuticsest. 2006NeuroTherapeutics PharmaChicago, IL, US · est. 2006

NeuroTherapeutics Pharma: A US-based biopharmaceutical firm specializing in neuropathic and acute pain treatments.

Public · $60.7M30
NeurolixisNeurolixisSan Diego, CA, USPharmaceuticalsest. 2011NeurolixisSan Diego, CA, US · est. 2011

San Diego-based Neurolixis, a biopharmaceutical firm innovating treatments for central nervous system diseases.

Seed · $15k6
NeuralyNeuralyGermantown, MD, USTherapeuticsest. 2016NeuralyGermantown, MD, US · est. 2016

Neuraly, Inc.: A biotech firm developing neuro-protective therapies for neurological disorders.

Series A · $36M125
NeuroTherapiaNeuroTherapiaOhio, IL, USTherapeuticsest. 2015NeuroTherapiaOhio, IL, US · est. 2015

NeuroTherpia, Inc.: Innovating therapies for neuroinflammatory diseases since 2015.

Series A · $11.5M4

Dean Petkanas's Similar Executives & Operators

Nugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakAchmad ZakyAchmad ZakyCo-Founder · BukalapakBo ZhangBo ZhangCo-Founder · DiDiWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Dean Petkanas

Benoit TasBenoit TasFounder · NeuroPathJordan DolesJordan DolesCo-Founder · NeuroX InnovationsMax DordevicMax DordevicCo-Founder · NeuroX1Keith SullivanKeith SullivanCEO · Neuronetics